In vitro assays using BaF-BO3 cells transfected with the hGH receptor confirmed that AOD9604 does not compete for the hGH receptor and does not induce cell proliferation unlike intact hGH establishing that it operates via a novel mechanism distinct from traditional hGH-stimulated pathways
This ensures safe and effective treatment for a wide range of patients
To review: a peptide is a short chain of amino acids that is linked by peptide (carboxyl group) bonds after a condensation reaction, removing H2O

Semaglutide is prescribed for: Weight loss in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) Weight loss in adult patients with an initial body mass index (BMI) of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (hypertension, type 2 diabetes mellitus, or dyslipidemia) Weight loss in pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex (obesity) Reducing the risk of major adverse cardiovascular events (non-fatal myocardial infarction, CV death, or non-fatal stroke) in adults with cardiovascular disease and either obesity or overweight Treating noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH, with moderate to advanced liver fibrosis (stages F2 to F3 fibrosis) in adults Patients taking semaglutide for any of these conditions, especially weight loss, are typically suggested to maintain a low-carb and low-fat diet

This is because NNMTi improves fat metabolism to assist weight loss, alleviates intestinal inflammation, and reduces gastrointestinal adverse reactions.These combined intervention studies provide novel strategies for clinical obesity management and expand the application scope of NNMTi